Cargando…

The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model

BACKGROUND: Weight gain is one of the consequences of estrogen deficiency and constitutes a major health problem. The present study highlights the effects of N-methyl pyrrolidone (NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized rat model. RESULTS: Ovariectomy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gjoksi, Bebeka, Ghayor, Chafik, Bhattacharya, Indranil, Zenobi-Wong, Marcy, Weber, Franz E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840488/
https://www.ncbi.nlm.nih.gov/pubmed/27110299
http://dx.doi.org/10.1186/s13148-016-0209-2
_version_ 1782428288820445184
author Gjoksi, Bebeka
Ghayor, Chafik
Bhattacharya, Indranil
Zenobi-Wong, Marcy
Weber, Franz E.
author_facet Gjoksi, Bebeka
Ghayor, Chafik
Bhattacharya, Indranil
Zenobi-Wong, Marcy
Weber, Franz E.
author_sort Gjoksi, Bebeka
collection PubMed
description BACKGROUND: Weight gain is one of the consequences of estrogen deficiency and constitutes a major health problem. The present study highlights the effects of N-methyl pyrrolidone (NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized rat model. RESULTS: Ovariectomy resulted in body weight gain, increased femoral marrow adipocytes, and hypertrophic adipocytes in white adipose tissue, distorted serum leptin, and TNF-α and PPARγ levels. Treatment with NMP normalized these parameters similar to the control group. In vitro, NMP inhibited the differentiation of 3T3-L1 pre-adipocytes and hMSCs, indicating its anti-adipogenic effect. Moreover, PPARγ was significantly reduced with NMP treatment in in vivo and in vitro experiments. NMP inhibited BRD2 and BRD4 binding in an AlphaScreen assay, with an IC50 of 3 and 4 mM, respectively. The effect of NMP was consistent with its role as a bromodomain inhibitor. CONCLUSIONS: Our data indicates that NMP inhibits the adipogenic effect of estrogen deficiency at the level of PPARγ expression by BRD4 inhibition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0209-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4840488
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48404882016-04-23 The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model Gjoksi, Bebeka Ghayor, Chafik Bhattacharya, Indranil Zenobi-Wong, Marcy Weber, Franz E. Clin Epigenetics Research BACKGROUND: Weight gain is one of the consequences of estrogen deficiency and constitutes a major health problem. The present study highlights the effects of N-methyl pyrrolidone (NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized rat model. RESULTS: Ovariectomy resulted in body weight gain, increased femoral marrow adipocytes, and hypertrophic adipocytes in white adipose tissue, distorted serum leptin, and TNF-α and PPARγ levels. Treatment with NMP normalized these parameters similar to the control group. In vitro, NMP inhibited the differentiation of 3T3-L1 pre-adipocytes and hMSCs, indicating its anti-adipogenic effect. Moreover, PPARγ was significantly reduced with NMP treatment in in vivo and in vitro experiments. NMP inhibited BRD2 and BRD4 binding in an AlphaScreen assay, with an IC50 of 3 and 4 mM, respectively. The effect of NMP was consistent with its role as a bromodomain inhibitor. CONCLUSIONS: Our data indicates that NMP inhibits the adipogenic effect of estrogen deficiency at the level of PPARγ expression by BRD4 inhibition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0209-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-22 /pmc/articles/PMC4840488/ /pubmed/27110299 http://dx.doi.org/10.1186/s13148-016-0209-2 Text en © Gjoksi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gjoksi, Bebeka
Ghayor, Chafik
Bhattacharya, Indranil
Zenobi-Wong, Marcy
Weber, Franz E.
The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
title The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
title_full The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
title_fullStr The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
title_full_unstemmed The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
title_short The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
title_sort bromodomain inhibitor n-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840488/
https://www.ncbi.nlm.nih.gov/pubmed/27110299
http://dx.doi.org/10.1186/s13148-016-0209-2
work_keys_str_mv AT gjoksibebeka thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT ghayorchafik thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT bhattacharyaindranil thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT zenobiwongmarcy thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT weberfranze thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT gjoksibebeka bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT ghayorchafik bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT bhattacharyaindranil bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT zenobiwongmarcy bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel
AT weberfranze bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel